January 20, 2012: Pfizer and Medivation, Inc have announced results from a Phase 3 trial (the CONCERT trial) that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease did not achieve statistically significant results for either of the two co-primary endpoints and that the companies are to discontinue development of dimebon for all indications and terminate the open-label extension study in Alzheimer’s disease. As a result, the companies will terminate their collaboration to co-develop and market dimebon.
“We recognise Alzheimer’s is a very complex disease,” said Steven J. Romano, MD, senior vice president, head of the Medicines Development Group of Pfizer’s Global Primary Care Business Unit. “Despite this disappointing result, Pfizer remains committed to advancing the science of Alzheimer’s disease, with the ultimate goal of delivering innovative and meaningful new treatment options to patients.”
- RSS Feed
